Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripertamab and Tacrolimus in Initial Minimal Change Disease
NCT06405100Phase 3Not yet recruiting
- Sponsor
- Air Force Medical University
- Start
- May 2024
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of ripertamab in minimal change disease (MCD), sponsored by Air Force Medical University. Planned start May 2024; status: not yet recruiting.
02
Drugs
ripertamab
03
Conditions
minimal change disease (MCD)
Beyond the preview
Go deeper on NCT06405100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06405100.